Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT00716066
Other study ID # 2260.00
Secondary ID NCI-2010-0040322
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date June 2008
Est. completion date January 31, 2030

Study information

Verified date January 2024
Source Fred Hutchinson Cancer Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This phase II trial studies the side effects and how well carmustine, etoposide, cytarabine and melphalan together with antithymocyte globulin before a stem cell transplant works in treating patients with autoimmune neurologic disease that did not respond to previous therapy. In autoimmune neurological diseases, the patient's own immune system 'attacks' the nervous system which might include the brain/spinal cord and/or the peripheral nerves. Giving high-dose chemotherapy, including carmustine, etoposide, cytarabine, melphalan, and antithymocyte globulin, before a stem cell transplant weakens the immune system and may help stop the immune system from 'attacking' a patient's nervous system. When the patient's own (autologous) stem cells are infused into the patient they help the bone marrow make red blood cells, white blood cells, and platelets so the blood counts can improve.


Description:

OUTLINE: Patients receive carmustine intravenously (IV) on day -6, etoposide IV and cytarabine IV twice daily (BID) on days -5 to -2, melphalan IV on day -1, and antithymocyte globulin IV on days -2 and -1. Patients then undergo autologous or syngeneic stem cell transplant on day 0. Patients also receive prednisone orally (PO) once daily (QD) on days 7-21, followed by 2 week taper. After completion of study treatment, patients are followed up at 3 months, 1 year, and then annually thereafter for up to 5 years.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 53
Est. completion date January 31, 2030
Est. primary completion date January 31, 2025
Accepts healthy volunteers No
Gender All
Age group N/A to 71 Years
Eligibility Inclusion Criteria: - Patients with an autoimmune disorder of the central or peripheral nervous system will be eligible; this will include: - Primary Central Nervous System (CNS) vasculitis - Rasmussen's encephalitis - Autoimmune peripheral neuropathy (anti-Hu [Anna-1], anti-GM1 [GD1b], anti-MAG, anti-ganglioside, anti-sulfatide) - Autoimmune cerebellar degeneration - Gait Ataxia with Late age Onset Polyneuropathy (GALOP) - Stiff Person Syndrome - Chronic Inflammatory Demyelinating Polyneuropathy - Myasthenia Gravis - Lambert-Eaton myasthenic syndrome - Human T-cell lymphotropic virus (HTLV)-1-associated myelopathy (HAM) / tropical spastic paraparesis (TSP) - Opsoclonus/myoclonus (anti-Ri) - Neuromyelitis optica - Multiple sclerosis - Other central or peripheral nervous system autoimmune diseases as approved by study neurologists and the Fred Hutchinson Cancer Research Center (FHCRC) faculty at Patient Care Conference (PCC) - Patients must satisfy the criteria for a diagnosis of one of the severe neurological autoimmune disorders outlined - Patients age =< 70 years - Evidence of disease activity as outlined (e.g. gadolinium enhancement on magnetic resonance imaging of the brain or clinical progression) - Patients must have failed at least 2 lines of standard therapy as outlined for the specific diseases - DONOR: Sibling of any patient enrolled on this protocol proven by ABO typing, human leukocyte antigen (HLA) typing and variable number tandem repeat (VNTR) analysis to be syngeneic with the patient (e.g. identical twin) - DONOR: Willing to undergo multiple apheresis procedures (except donors < 12 years who will undergo bone marrow harvests) Exclusion Criteria: - Age >= 71 years - Pregnancy or expressed plans to become pregnant within 1 year of the procedure - Patients who are serologically positive for human immunodeficiency virus (HIV) - Patients with pulmonary, cardiac, hepatic or renal impairment that would limit their ability to receive cytoreductive therapy and compromise their survival; this should include patients with any of the following: - Severe pulmonary dysfunction associated with a carbon monoxide diffusing capacity (DLCO) (corrected for hemoglobin) < 60%, or requires supplemental oxygen; patients who are unable to perform pulmonary function test (because of underlying disease) will be excluded if the oxygen saturation is < 92% on room air - Uncontrolled malignant arrhythmias, or clinical evidence of congestive heart failure (New York class III-IV) or ejection fraction < 50% - Renal disease with estimated glomerular filtration rate (GFR) by creatinine clearance or iothalamate clearance < 50 ml/min/1.73 m^2 body surface area - Serum glutamate pyruvate transaminase (SGPT)/aspartate aminotransferase (AST) > 3 times normal or direct bilirubin greater than 2.5 mg/dL on two repeated tests - Active uncontrolled infection - Demonstrated lack of compliance with prior medical care - Patients whose life expectancy is limited by illness other than their neurological condition - Patients with evidence of myelodysplasia - Active malignancy (excluding localized squamous cell or basal cell carcinoma of the skin) - DONOR: Inadequate documentation that donor and recipient are syngeneic - DONOR: Donors who do not fulfill criteria as apheresis donors as established by institutional guidelines - DONOR: Concordant for autoimmune neurological disease(s) as determined by neurological evaluation

Study Design


Related Conditions & MeSH terms

  • Autoimmune Disease
  • Autoimmune Diseases
  • Autoimmune Diseases of the Nervous System
  • Autoimmune Nervous System Disorder
  • Autologous Transplant Autoimmune
  • Central Nervous System Vasculitis
  • Cerebellar Degeneration
  • Chronic Inflammatory Demyelinating Polyneuropathy
  • CIDP Transplant
  • Encephalitis
  • HCT for Neurologic Autoimmune Disorders
  • Lambert Eaton Myasthenic Syndrome
  • Lambert-Eaton Myasthenic Syndrome
  • MS Stem Cell Transplant
  • Multiple Sclerosis
  • Multiple Sclerosis Stem Cell Transplant
  • Multiple Sclerosis Transplant
  • Muscle Weakness
  • Myasthenia Gravis
  • Myasthenia Gravis Transplant
  • Myoclonus
  • Nervous System Diseases
  • Neurologic Autoimmune Disease
  • Neuromyelitis Optica
  • Ocular Motility Disorders
  • Opsoclonus Myoclonus Syndrome
  • Opsoclonus-Myoclonus Syndrome
  • Polyneuropathies
  • Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
  • Rasmussen Subacute Encephalitis
  • Sclerosis
  • Stiff Person Syndrome
  • Stiff-Person Syndrome
  • Syndrome
  • Vasculitis
  • Vasculitis, Central Nervous System

Intervention

Biological:
Anti-Thymocyte Globulin
Given IV
Procedure:
Autologous Hematopoietic Stem Cell Transplantation
Undergo autologous or syngeneic stem cell transplantation
Drug:
Carmustine
Given IV
Cytarabine
Given IV
Etoposide
Given IV
Other:
Laboratory Biomarker Analysis
Correlative studies
Drug:
Melphalan
Given IV
Procedure:
Peripheral Blood Stem Cell Transplantation
Undergo autologous or syngeneic stem cell transplantation
Drug:
Prednisone
Given PO
Procedure:
Syngeneic Bone Marrow Transplantation
Undergo syngeneic bone marrow transplantation

Locations

Country Name City State
United States Colorado Blood Cancer Institute Denver Colorado
United States Fred Hutch/University of Washington Cancer Consortium Seattle Washington
United States Swedish Medical Center-First Hill Seattle Washington

Sponsors (1)

Lead Sponsor Collaborator
Fred Hutchinson Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of grades 4-5 regimen-related toxicity Assessed by the Regimen Related Toxicity Scale. Using the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0. The development of a grade 4 to 5 toxicity of any of the included major organ systems within the first 365 days after transplant will be defined as regimen-related toxicity. Up to 1 year post-transplant
Secondary Transplant-related mortality Defined as death within the first 100 days of transplant due to transplant-related complications. Within 100 days post-transplant
Secondary Disease responses Assessed by clinical, laboratory and radiologic evaluation Up to 5 years
Secondary Engraftment kinetics Monitored for engraftment kinetics of granulocytes, platelets and red cells post-transplant. Over first 60 days post-transplant
Secondary Number of subjects achieving greater than or equal to 4.0 x 10^6 CD34+ cells/kg, after up to two peripheral blood stem cell mobilizations Efficacy of peripheral blood stem cell mobilization as evaluated by total number of harvested CD34+cells/kg, for autologous transplant. Baseline to post mobilization, assessed up to 20 days after starting final mobilization (up to two mobilizations)
Secondary Number of subjects with an exacerbation of autoimmune disease symptoms secondary to G-CSF (filgrastim) during peripheral blood stem cell mobilization Subjects are evaluated by standardized clinical neurologic tests specific to autoimmune disease type. Baseline to post mobilization, assessed up to 20 days after starting final mobilization (up to two mobilizations)
See also
  Status Clinical Trial Phase
Completed NCT05039190 - Evaluate the Efficacy and Safety of HBM9161(HL161)Subcutaneous Injection in Patients With Generalized MG Patients Phase 3
Recruiting NCT04561557 - Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System Early Phase 1
Completed NCT01727193 - The Efficacy and Safety of Leflunomide or Azathioprine Therapy in Myasthenia Gravis Patients After Expand Thymectomy Phase 3
Completed NCT00285350 - Mycophenolate Mofetil in Myasthenia Gravis Phase 3
Recruiting NCT05890833 - The Risk of Falls Index for Patients With Neuromuscular Disorders
Completed NCT05694234 - Influences of Sugammadex on Postoperative Progress in Patients With Myasthenia Gravis Undergoing Video-assisted Thoracoscopic Thymectomy: Retrospective Study
Recruiting NCT05635266 - Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Not yet recruiting NCT04965987 - Oxaloacetate in Myasthenia Gravis Phase 1
Not yet recruiting NCT05095103 - Immune Profiles in Myasthenia Gravis
Completed NCT02774239 - A Pilot Trial To Assess The Feasibility And Efficacy Of SCIG In Patients With MG Exacerbation (SCIG-MG) Phase 3
Completed NCT02066519 - Benefits and Tolerance of Exercise in Patients With Generalized and Stabilized Myasthenia Gravis N/A
Terminated NCT02102594 - Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB) Phase 2
Completed NCT02118805 - Innovative Measures of Speech and Swallowing Dysfunction in Neurological Disorders
Terminated NCT01828294 - Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis Phase 1
Terminated NCT00727194 - Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis Phase 2
Completed NCT04590716 - Help Build an A.I. Model to Predict Myasthenia Gravis Symptom Patterns and Flares
Recruiting NCT04837625 - Study of Myasthenic Crisis in China
Not yet recruiting NCT01469858 - Perception and Multisensory Integration in Neurological Patients Using fMRI N/A
Completed NCT05408702 - Exercise in Autoimmune Myasthenia Gravis and Myasthenic Syndromes
Completed NCT03205306 - Myasthenia Gravis and Psyche